Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 44.4% in February

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 2,310,000 shares, an increase of 44.4% from the January 31st total of 1,600,000 shares. Based on an average daily volume of 2,460,000 shares, the short-interest ratio is currently 0.9 days.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently modified their holdings of ITCI. Vanguard Group Inc. boosted its stake in Intra-Cellular Therapies by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after acquiring an additional 93,107 shares in the last quarter. Wasatch Advisors LP boosted its position in shares of Intra-Cellular Therapies by 3.5% during the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock worth $281,601,000 after purchasing an additional 130,351 shares in the last quarter. Norges Bank acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at about $268,347,000. Invesco Ltd. increased its position in Intra-Cellular Therapies by 2.9% in the 4th quarter. Invesco Ltd. now owns 3,077,174 shares of the biopharmaceutical company’s stock valued at $257,006,000 after buying an additional 87,582 shares in the last quarter. Finally, Bellevue Group AG raised its stake in Intra-Cellular Therapies by 0.6% during the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock worth $181,873,000 after buying an additional 14,342 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ:ITCI traded up $3.08 during trading on Monday, reaching $131.28. The stock had a trading volume of 7,155,386 shares, compared to its average volume of 3,931,705. Intra-Cellular Therapies has a 52 week low of $63.30 and a 52 week high of $131.35. The firm’s fifty day moving average is $114.58 and its 200 day moving average is $91.72. The stock has a market cap of $13.96 billion, a price-to-earnings ratio of -150.89 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. On average, research analysts forecast that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ITCI shares. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Royal Bank of Canada reiterated a “sector perform” rating and set a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. JPMorgan Chase & Co. boosted their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Finally, Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Intra-Cellular Therapies currently has a consensus rating of “Hold” and a consensus target price of $106.08.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.